[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335120-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335120-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","t-cell-neoplasms-after-b-cell-neoplasms-the-pre-car-t-era","T-Cell Neoplasms after B-Cell Neoplasms - The pre-CAR-T Era","","Letter to the editor analyzing baseline incidence and risk of T-cell lymphomas/leukemias among patients with prior B-cell lymphomas/leukemias in the pre-CAR-T era. Using 17 US population-based cancer registry data (2000–2017), authors estimate incidence rates per 100,000 persons, standardized incidence ratios, and excess absolute risks per 100,000 person-years matched to general population. Among 235,665 treated B-cell lymphoma/leukemia patients, 298 subsequent T-cell cases were observed, with risks varying by time since diagnosis, age, and T-cell subtype. Findings highlight challenges in defining an appropriate expected rate and support continued registry participation and biological specimen collection to clarify causality as CAR-T use expands.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/t-cell-neoplasms-after-b-cell-neoplasms-the-pre-car-t-era/335120/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/t-cell-neoplasms-after-b-cell-neoplasms-the-pre-car-t-era/335120.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are T-cell lymphomas/leukemias after CAR-T therapy a critical question?","Question",{"text":63,"@type":64},"Reports of T-cell lymphomas/leukemias after CAR-T for B-cell lymphomas/leukemias raise concern as a potential therapy-related adverse effect. Determining whether observed rates exceed background risk depends on understanding pre-CAR-T baseline risks.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study quantify baseline T-cell lymphoma/leukemia risk in the pre-CAR-T era?",{"text":68,"@type":64},"Incidence rates per 100,000 persons, standardized incidence ratios, and excess absolute risks were calculated using observed cases among B-cell lymphoma/leukemia survivors and expected cases from a matched general population sample across 17 US cancer registries (2000–2017).",{"name":70,"@type":61,"acceptedAnswer":71},"What did the authors find about observed versus expected T-cell lymphoma/leukemia cases?",{"text":72,"@type":64},"Among 235,665 B-cell lymphoma/leukemia patients, 298 subsequent T-cell lymphomas/leukemias were identified (IR=22.7). In the general population, 62.4 cases were expected (IR=4.7), yielding an SIR of 4.8 and an excess absolute risk of 18 cases per 100,000 person-years.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335120,1790013094,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":55,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>N Engl J Med. Author manuscript; available in PMC 2024 August 16. |\n| --- | --- |\n\nPublished in final edited form as:  \nN Engl J Med. 2024 August 15; 391(7): 662–664. doi:10.1056/NEJMc2408029 .  \nT-Cell Neoplasms after B-Cell Neoplasms – The pre-CAR-T Era  \nGraça M. Dores, M.D., M.P.H. , Lindsay M. Morton, Ph.D.  \nNational Cancer Institute, Bethesda, MD  \nTo the Editor:  \nRecent reports ofT-cell lymphomas/leukemias after chimeric antigen receptor T-cell (CART) therapy for relapsed/refractory B-cell lymphomas/leukemias have garnered attention asa potential CAR-T therapy-related adverse effect.1,2 However, it has long been known that B-cell lymphoma/leukemia patients have increased risk of subsequent malignancies, including T-cell lymphomas/leukemias, related to treatments, immunosuppression, and other risk factors.3–5 Whether T-cell lymphomas/leukemias following CAR-T therapy for B-cell lymphomas/leukemias occur more often than expected is an unanswered but critical question because of disease-and prior treatment-related risk factors and the rarity ofT-cell lymphomas/leukemias.  \nTo better understand baseline T-cell lymphoma/leukemia risks after B-cell lymphoma/ leukemia in the pre-CAR-T era, we quantified incidence rates per 100,000 persons (IRs), standardized incidence ratios (SIRs), and excess absolute risks per 100,000 person-years (EARs) ofT-cell lymphomas/leukemias in B-cell lymphoma/leukemia patients and an age-, sex-, and race and ethnicity-matched general population sample from 17 US populationbased cancer registry data (2000–2017). IRs were calculated as the observed (B-cell lymphoma/leukemia survivors) or expected (general population) number of cases divided by the total person-years at risk.  \nAmong 235,665 B-cell lymphoma/leukemia patients treated with initial chemo/ immunotherapy, we identified 298 subsequent T-cell lymphomas/leukemias (IR=22.7) . In the general population, 62.4 cases (IR=4.7) were expected, representing an SIR=4.8 and EAR=18 cases. IRs, SIRs, and EARs were highly variable by time since B-cell lymphoma/ leukemia diagnosis, age at diagnosis, and T-cell lymphoma/leukemia subtype (Figure 1) . Despite including 26.5% of the US population over an 18-year period, the rarity ofT-cell lymphomas/leukemias precluded IR and SIR estimation when stratifying by B-and T-cell lymphoma/leukemia subtypes simultaneously; however, overall T-cell lymphoma/leukemia risks also varied substantially by B-cell lymphoma/leukemia subtype.  \nThese population-based data emphasize the difficulty of accurately quantifying an“expected” T-cell lymphomas/leukemias rate for patients treated with CAR-T therapy.  \nThis Author Accepted Manuscript is licensed for use under the CC-BY-NC-ND license.  \n[mortonli@mail.nih.gov](mortonli@mail.nih.gov) .  \nDisclosure forms provided by the authors are available with the full text of this [letter at](letter at NEJM.org)[ NEJM.org](letter at NEJM.org).  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nDores and Morton Page 2  \nFirst, general population T-cell lymphoma/leukemia rates are not appropriate for B-cell lymphoma/leukemia survivors because they have elevated risk in the pre-CAR-T era.  \nSecond, T-cell lymphomas/leukemias are too rare to reliably estimate expected rates after B-cell lymphoma/leukemia.  \nPatients treated with CAR-T therapy should continue to be encouraged to participate in registries collecting detailed treatment information and patient outcomes so that future studies can identify factors contributing to T-cell lymphoma/leukemia risk following B-cell lymphoma/leukemia. Biologic specimen collection will enable detailed molecular studies to potentially detect the CAR transgene, quantify allele frequency, and assess viral integration to further assess causality. The importance of clarifying CAR-T therapy-related adverse effects is ","cbCaim8Mn80QWQz8","https://ap.wps.com/l/cbCaim8Mn80QWQz8","pdf",465071,"English","# Background\n# Methods\n## Data sources and risk estimation\n# Results\n## Observed and expected incidence\n# Implications for CAR-T safety assessment\n# Acknowledgments and data sharing","[{\"question\":\"Why are T-cell lymphomas/leukemias after CAR-T therapy a critical question?\",\"answer\":\"Reports of T-cell lymphomas/leukemias after CAR-T for B-cell lymphomas/leukemias raise concern as a potential therapy-related adverse effect. Determining whether observed rates exceed background risk depends on understanding pre-CAR-T baseline risks.\"},{\"question\":\"How did the study quantify baseline T-cell lymphoma/leukemia risk in the pre-CAR-T era?\",\"answer\":\"Incidence rates per 100,000 persons, standardized incidence ratios, and excess absolute risks were calculated using observed cases among B-cell lymphoma/leukemia survivors and expected cases from a matched general population sample across 17 US cancer registries (2000–2017).\"},{\"question\":\"What did the authors find about observed versus expected T-cell lymphoma/leukemia cases?\",\"answer\":\"Among 235,665 B-cell lymphoma/leukemia patients, 298 subsequent T-cell lymphomas/leukemias were identified (IR=22.7). In the general population, 62.4 cases were expected (IR=4.7), yielding an SIR of 4.8 and an excess absolute risk of 18 cases per 100,000 person-years.\"}]","T-Cell Neoplasms after B-Cell Neoplasms - The pre-CAR-T Era | PDF",1790009731]